Lupin gets USFDA nod for generic ulcer drug

Drug firm Lupin has received approval from US health regulator USFDA to market generic Omeprazole delayed-release capsules, used to treat ulcer, in the American market.

The company has received final approval for its Omeprazole delayed-release capsules (40 mg) from the United States Food and Drugs Administration (USFDA), Lupin Ltd said in a statement.

The Mumbai-based company's Omeprazole delayed-release capsules are the generic equivalent of AstraZeneca's Prilosec delayed-release capsules, which are indicated for the treatment of duodenal ulcer, gastric ulcer and gastro esophageal reflux disease (GERD).

The drug is also used for healing of erosive esophagitis and pathological hypersecretory conditions.

According to IMS MAT June data, Prilosec had annual US sales of USD 185 million.

Lupin shares today ended at Rs 1,898.50 apiece on the BSE, up 4.79 per cent from previous close.